MARKET

SLP

SLP

Simulations Plus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.98
+4.94
+7.48%
After Hours: 71.40 +0.42 +0.59% 16:44 09/25 EDT
OPEN
67.00
PREV CLOSE
66.04
HIGH
71.27
LOW
67.00
VOLUME
454.13K
TURNOVER
--
52 WEEK HIGH
73.58
52 WEEK LOW
26.00
MARKET CAP
1.39B
P/E (TTM)
141.31
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
Simulations Plus today announced that it has partnered with a large pharmaceutical company to validate the AIDD Module in ADMET Predictor 10.0 (APX).
Business Wire · 3d ago
Simulations Plus inks agreement to validate AI-driven drug design capabilities in ADMET predictor
Simulations Plus (SLP) entered into a collaborative research agreement with a large pharmaceutical company to evaluate the new AIDD Module in the recently launched version of ADMET Predictor.Pursuant to the
Seekingalpha · 3d ago
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
Simulations Plus today announced the release of ADMET Predictor 10.0 (APX) - a major upgrade with new AI-Driven Drug Design & Transporters Modules.
Business Wire · 09/15 12:30
Simulations Plus started at outperform with $79 stock price target at Oppenheimer
SLP | Complete Simulations Plus Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/08 12:45
Do Institutions Own Simulations Plus, Inc. (NASDAQ:SLP) Shares?
The big shareholder groups in Simulations Plus, Inc. (NASDAQ:SLP) have power over the company. Generally speaking, as...
Simply Wall St. · 09/03 18:30
Evogene: Hidden Gems Of Computational Predictive Biology (Part 3 Of 4) - Ag Plenus (Novel Herbicides And Pesticides)
Evogene's 100% owned subsidiary AgPlenus utilizes Evogene's computational predictive biology platform to develop Ag-Chemicals (novel herbicides, insecticides and other crop control products).AgPlenus has entered into a number of collaboration licensing agreements with various multi-national companies including BASF, Corteva, and ICL. ARK Invest just announced a $7 million investment in EVGN.AgPlenus has a portfolio of a novel mode of action herbicides and insecticides. With more than 10 "Hits", its most advanced novel herbicide will likely be a "Lead" in 2020.There is an immediate need for novel mode of action herbicides, insecticides and other crop control products. These are enormous markets estimated to be in excess of $70 billion by 2022.Evogene remains grossly undervalued when taking into account its computational platform, cash balance, internal division, and 4 valuable subsidiaries. This is the 3rd of a 4-part series on Evogene. This article's focus is on Evogene's 100% subsidiary AgPlenus.
Seekingalpha · 09/02 14:48
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations
Business Wire · 09/02 13:30
Simulations Plus Subsidiary DILIsym Services Highlight's FDA's Use Of Co's Software In Simulations
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations FDA Review Document and New Toxicological Sciences Publication Detail Results DILIsym Services, Inc., a Simulations Plus company (NASDAQ:SLP) and a
Benzinga · 09/02 12:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLP. Analyze the recent business situations of Simulations Plus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLP stock price target is 75.33 with a high estimate of 79.00 and a low estimate of 72.00.
EPS
Institutional Holdings
Institutions: 191
Institutional Holdings: 11.03M
% Owned: 56.27%
Shares Outstanding: 19.61M
TypeInstitutionsShares
Increased
52
2.13M
New
54
245.15K
Decreased
41
1.16M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.77%
Healthcare Equipment & Supplies
+2.02%
Key Executives
Chairman/Director
Walter Woltosz
Chief Executive Officer
Shawn O'Connor
Chief Financial Officer
John Kneisel
Corporate Executive
John DiBella
Corporate Executive
Jill Fiedler-Kelly
Other
Thaddeus Grasela
Independent Director
Lisa LaVange
Independent Director
John Paglia
Independent Director
David Ralph
Independent Director
Daniel Weiner
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/09/2020
Dividend USD 0.06
07/24/2020
04/09/2020
Dividend USD 0.06
04/23/2020
01/09/2020
Dividend USD 0.06
01/24/2020
10/14/2019
Dividend USD 0.06
10/24/2019
07/10/2019
Dividend USD 0.06
07/24/2019
04/09/2019
Dividend USD 0.06
04/23/2019
01/09/2019
Dividend USD 0.06
01/24/2019
10/22/2018
Dividend USD 0.06
10/31/2018
07/06/2018
Dividend USD 0.06
07/25/2018
04/09/2018
Dividend USD 0.06
04/24/2018
01/16/2018
Dividend USD 0.06
01/25/2018
11/01/2017
Dividend USD 0.06
11/10/2017
07/18/2017
Dividend USD 0.05
07/26/2017
04/26/2017
Dividend USD 0.05
05/04/2017
01/20/2017
Dividend USD 0.05
01/26/2017
10/31/2016
Dividend USD 0.05
11/08/2016
08/01/2016
Dividend USD 0.05
08/09/2016
04/22/2016
Dividend USD 0.05
04/28/2016
01/19/2016
Dividend USD 0.05
01/27/2016
10/28/2015
Dividend USD 0.05
11/05/2015
07/13/2015
Dividend USD 0.05
07/21/2015
04/29/2015
Dividend USD 0.05
05/07/2015
01/15/2015
Dividend USD 0.05
01/22/2015
10/28/2014
Dividend USD 0.05
11/05/2014
07/25/2014
Dividend USD 0.05
07/31/2014
04/30/2014
Dividend USD 0.05
05/07/2014
02/05/2014
Dividend USD 0.05
02/12/2014
10/29/2013
Dividend USD 0.04
11/06/2013
07/30/2013
Dividend USD 0.03
08/08/2013
04/26/2013
Dividend USD 0.03
05/03/2013
12/13/2012
Dividend USD 0.14
12/20/2012
10/26/2012
Dividend USD 0.05
11/06/2012
07/27/2012
Dividend USD 0.05
08/03/2012
04/17/2012
Dividend USD 0.05
04/25/2012
02/10/2012
Dividend USD 0.05
02/16/2012
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Simulations Plus, Inc. stock information, including NASDAQ:SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.